Kilitch Drugs (India) Limited (NSE:KILITCH) — Market Cap & Net Worth
Market Cap & Net Worth: Kilitch Drugs (India) Limited (KILITCH)
Kilitch Drugs (India) Limited (NSE:KILITCH) has a market capitalization of $72.16 Million (Rs6.67 Billion) as of August 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #20432 globally and #1137 in its home market, demonstrating a 6.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kilitch Drugs (India) Limited's stock price Rs190.86 by its total outstanding shares 34961564 (34.96 Million). See Kilitch Drugs (India) Limited (KILITCH) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Kilitch Drugs (India) Limited Market Cap History: 2015 to 2026
Kilitch Drugs (India) Limited's market capitalization history from 2015 to 2026. Data shows growth from $17.00 Million to $72.16 Million (16.21% CAGR).
Kilitch Drugs (India) Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kilitch Drugs (India) Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.07x
Kilitch Drugs (India) Limited's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.50x
Kilitch Drugs (India) Limited's market cap is 0.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $13.86 Million | $209.85 Million | -$111.91 Million | 0.07x | N/A |
| 2017 | $32.79 Million | $271.61 Million | -$88.90 Million | 0.12x | N/A |
| 2018 | $60.09 Million | $510.12 Million | $51.52 Million | 0.12x | 1.17x |
| 2019 | $48.17 Million | $824.90 Million | $38.30 Million | 0.06x | 1.26x |
| 2020 | $36.43 Million | $533.20 Million | $8.42 Million | 0.07x | 4.33x |
| 2021 | $89.87 Million | $681.28 Million | $36.71 Million | 0.13x | 2.45x |
| 2022 | $58.85 Million | $1.14 Billion | $73.67 Million | 0.05x | 0.80x |
| 2023 | $139.63 Million | $1.40 Billion | $104.48 Million | 0.10x | 1.34x |
| 2024 | $123.33 Million | $1.54 Billion | $146.01 Million | 0.08x | 0.84x |
| 2025 | $132.41 Million | $1.98 Billion | $267.01 Million | 0.07x | 0.50x |
Competitor Companies of KILITCH by Market Capitalization
Companies near Kilitch Drugs (India) Limited in the global market cap rankings as of August 4, 2026.
Key companies related to Kilitch Drugs (India) Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Kilitch Drugs (India) Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Kilitch Drugs (India) Limited's market cap moved from $17.00 Million to $ 72.16 Million, with a yearly change of 16.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs72.16 Million | -45.50% |
| 2025 | Rs132.41 Million | +7.36% |
| 2024 | Rs123.33 Million | -11.67% |
| 2023 | Rs139.63 Million | +137.26% |
| 2022 | Rs58.85 Million | -34.52% |
| 2021 | Rs89.87 Million | +146.70% |
| 2020 | Rs36.43 Million | -24.37% |
| 2019 | Rs48.17 Million | -19.84% |
| 2018 | Rs60.09 Million | +83.25% |
| 2017 | Rs32.79 Million | +136.51% |
| 2016 | Rs13.86 Million | -18.42% |
| 2015 | Rs17.00 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Kilitch Drugs (India) Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $72.16 Million USD |
| MoneyControl | $72.16 Million USD |
| MarketWatch | $72.16 Million USD |
| marketcap.company | $72.16 Million USD |
| Reuters | $72.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, ant… Read more